MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-13-2026
Protalix BioTherapeutics Total Non Current Liabilities 2011-2026 | PLX
Annual Total Non Current Liabilities Protalix BioTherapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7.6 M | 4.58 M | 5.34 M | 34 M | 46.5 M | 8.5 M | 75.5 M | 88.7 M | 80.8 M | 26 M | 75.1 M | 108 M | 114 M | 56.3 M | 59.2 M | 57.1 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 114 M | 4.58 M | 52.9 M |
Quarterly Total Non Current Liabilities Protalix BioTherapeutics
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7.72 M | 7.41 M | 4.49 M | 4.36 M | 4.91 M | 4.99 M | - | 5.96 M | 26.3 M | 34 M | 34 M | 33.9 M | 39.6 M | 40.5 M | 46.5 M | 40.5 M | 8.12 M | 7.43 M | 8.5 M | 8.5 M | 8.5 M | 8.5 M | 75.5 M | 75.5 M | 75.5 M | 75.5 M | 88.7 M | 88.7 M | 88.7 M | 88.7 M | 78.9 M | 78.9 M | 78.9 M | 78.9 M | 26 M | 26 M | 26 M | 26 M | 75.1 M | 75.1 M | 75.1 M | 75.1 M | 69.6 M | 108 M | 108 M | 108 M | 114 M | 114 M | 114 M | 114 M | 56.3 M | 56.3 M | 56.3 M | 56.3 M | 59.2 M | 59.2 M | 59.2 M | 59.2 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 114 M | 4.36 M | 53.9 M |
Total Non Current Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Non Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
79.1 K | - | 5743.5 % | $ 69.7 M |  Canada |
 |
MorphoSys AG
MOR
|
40.2 M | - | 2.43 % | $ 254 M |  Germany |
 |
Happiness Biotech Group Limited
HAPP
|
158 K | - | 1.35 % | $ 17.8 M |  China |
 |
AgeX Therapeutics
AGE
|
1.53 M | - | -10.17 % | $ 12.2 K |  USA |
 |
I-Mab
IMAB
|
131 M | - | - | $ 866 M | China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
4.83 B | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
2.02 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
184 M | - | 2.54 % | $ 160 B | France |
 |
AstraZeneca PLC
AZN
|
34.7 B | - | - | $ 96.9 B |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
6.39 M | - | -1.52 % | $ 24.7 M | USA |
 |
Athira Pharma
ATHA
|
876 K | - | - | $ 269 M | USA |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
7.32 M | - | 0.74 % | $ 768 M |  Israel |
 |
Abcam plc
ABCM
|
128 M | - | - | $ 4.9 B | Britain |
 |
Galera Therapeutics
GRTX
|
64 M | - | -32.59 % | $ 7.61 M | USA |
 |
Midatech Pharma plc
MTP
|
645 K | - | -18.52 % | $ 27.3 M | Britain |
 |
Esperion Therapeutics
ESPR
|
355 M | $ 3.13 | - | $ 651 M | USA |
 |
Eton Pharmaceuticals
ETON
|
4.56 M | $ 32.59 | -6.89 % | $ 877 M | USA |
|
Forte Biosciences
FBRX
|
10.5 M | $ 21.59 | -1.86 % | $ 280 M | USA |
 |
Affimed N.V.
AFMD
|
13.4 M | - | -34.95 % | $ 21.5 M | Germany |
 |
Институт стволовых клеток человека
ISKJ
|
541 M | - | - | - |  Russia |
 |
Celyad Oncology SA
CYAD
|
4.97 M | - | - | $ 12.5 M |  Belgium |
 |
Berkeley Lights
BLI
|
22.3 M | - | -7.31 % | $ 87 M | USA |
 |
Generation Bio Co.
GBIO
|
132 M | - | - | $ 344 M | USA |
 |
IMV
IMV
|
8.95 M | - | - | $ 13.1 M | Canada |
 |
Akero Therapeutics
AKRO
|
1.52 M | - | - | $ 3.67 B | USA |
 |
BioNTech SE
BNTX
|
622 M | $ 92.14 | 1.33 % | $ 22.3 B | Germany |
 |
Grifols, S.A.
GRFS
|
10.6 B | $ 7.98 | -1.6 % | $ 5.42 B |  Spain |
 |
Akouos
AKUS
|
12 M | - | 0.23 % | $ 488 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
50.6 M | $ 1.7 | 3.03 % | $ 452 M | Britain |
 |
Ayala Pharmaceuticals
AYLA
|
497 K | - | - | $ 7.46 M | Israel |
 |
Heron Therapeutics
HRTX
|
14.6 M | $ 0.86 | -1.42 % | $ 143 M | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
1.06 M | - | -4.36 % | $ 27 M | USA |
 |
Gracell Biotechnologies
GRCL
|
51.9 M | - | - | $ 3.37 B | China |
 |
Compugen Ltd.
CGEN
|
31.3 M | $ 2.8 | 7.28 % | $ 262 M | Israel |
 |
Anika Therapeutics
ANIK
|
26.1 M | $ 14.88 | -0.93 % | $ 213 M | USA |
 |
Advaxis
ADXS
|
16 M | - | -9.65 % | $ 45.9 M | USA |
 |
Incyte Corporation
INCY
|
315 M | $ 97.16 | -0.26 % | $ 19 B | USA |
 |
Ionis Pharmaceuticals
IONS
|
1.28 B | $ 75.56 | -0.29 % | $ 12.1 B | USA |
 |
Aeterna Zentaris
AEZS
|
14 M | - | 5.93 % | $ 314 M | Canada |
 |
Aeglea BioTherapeutics
AGLE
|
4.74 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
112 M | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
4.15 M | - | - | $ 26.5 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
1.19 M | $ 3.4 | -1.16 % | $ 5.6 M | Israel |
 |
AIkido Pharma
AIKI
|
2.29 M | - | 1.93 % | $ 17.4 M | USA |
 |
Aptose Biosciences
APTO
|
27.9 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
114 K | - | -39.0 % | $ 4.57 M | USA |
 |
Coherus BioSciences
CHRS
|
189 M | $ 1.61 | 2.55 % | $ 189 M | USA |
 |
Albireo Pharma
ALBO
|
79.1 M | - | -0.23 % | $ 916 M | USA |